home / stock / ipsc / ipsc quote
Last: | $2.475 |
---|---|
Change Percent: | 0.0% |
Open: | $2.43 |
Close: | $2.475 |
High: | $2.52 |
Low: | $2.31 |
Volume: | 181,620 |
Last Trade Date Time: | 07/23/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$2.475 | $2.43 | $2.475 | $2.52 | $2.31 | 181,620 | 07-23-2024 |
$2.43 | $2.34 | $2.43 | $2.44 | $2.2 | 391,210 | 07-22-2024 |
$2.5 | $2.67 | $2.5 | $2.7 | $2.48 | 121,760 | 07-19-2024 |
$2.66 | $2.97 | $2.66 | $3 | $2.62 | 210,090 | 07-18-2024 |
$3 | $3.25 | $3 | $3.26 | $2.945 | 195,412 | 07-17-2024 |
$3.29 | $2.75 | $3.29 | $3.29 | $2.75 | 386,979 | 07-16-2024 |
$2.75 | $2.98 | $2.75 | $3.079 | $2.6001 | 314,238 | 07-15-2024 |
$2.98 | $2.58 | $2.98 | $3.1 | $2.57 | 459,280 | 07-12-2024 |
$2.58 | $2.45 | $2.58 | $2.61 | $2.38 | 513,228 | 07-11-2024 |
$2.36 | $2.39 | $2.36 | $2.39 | $2.24 | 99,759 | 07-10-2024 |
$2.39 | $2.29 | $2.39 | $2.4 | $2.25 | 123,394 | 07-09-2024 |
$2.3 | $2.19 | $2.3 | $2.39 | $2.19 | 132,250 | 07-08-2024 |
$2.24 | $2.28 | $2.24 | $2.3 | $2.18 | 155,819 | 07-05-2024 |
$2.27 | $2.22 | $2.27 | $2.32 | $2.18 | 68,720 | 07-04-2024 |
$2.27 | $2.22 | $2.27 | $2.32 | $2.18 | 68,720 | 07-03-2024 |
$2.21 | $2.39 | $2.21 | $2.4 | $2.21 | 143,579 | 07-02-2024 |
$2.41 | $2.52 | $2.41 | $2.615 | $2.38 | 190,476 | 07-01-2024 |
$2.55 | $2.53 | $2.55 | $2.675 | $2.42 | 3,167,222 | 06-28-2024 |
$2.53 | $2.48 | $2.53 | $2.67 | $2.48 | 271,659 | 06-27-2024 |
$2.46 | $2.57 | $2.46 | $2.57 | $2.46 | 165,036 | 06-26-2024 |
News, Short Squeeze, Breakout and More Instantly...
Century Therapeutics Inc. Company Name:
IPSC Stock Symbol:
NASDAQ Market:
Century Therapeutics Inc. Website:
In ongoing dose escalation, CNTY-101 has demonstrated a manageable safety profile with no observed DLTs or GvHD and with majority of patients treated in outpatient setting Encouraging preliminary efficacy in heavily pretreated R/R NHL at initial dose levels Novel cell-free DNA m...
In vitro data showcases CNTY-101’s ability to induce CD19-specific cytolysis of B-cells and potential to treat B-cell driven autoimmune diseases including systemic lupus erythematosus (SLE) Preclinical data demonstrates potential utility of using a synthetic ligand targeting CD30...
- Announced plans to pursue additional autoimmune disease regulatory filings for its iPSC derived NK cell therapy, CNTY-101, beyond systemic lupus erythematosus (SLE) - Closed $60 million private placement led by Bain Capital Life Sciences supporting accelerated expansion in autoim...